Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 9/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286069 | 1.00 | ALOX5 (0.43) | ALOX5PSEN1PTGS1PTGS2CYP1A2 | |
| SCHEMBL1285627 | 0.85 | CYP19A1 (0.44) | ALOX5PSEN1PTGS1PTGS2CYP1A2 | |
| SCHEMBL7530465 | 0.79 | CYP3A4 (0.42) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL4473264 | 0.77 | ALOX5 (0.48) | ALOX5PSEN1 | |
| SCHEMBL4475158 | 0.77 | ALOX5 (0.48) | ALOX5PSEN1 | |
| SCHEMBL5770249 | 0.77 | ALOX5 (0.47) | ALOX5 | |
| SCHEMBL14283909 | 0.77 | CYP3A4 (0.47) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL14283899 | 0.77 | CYP3A4 (0.47) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL5769978 | 0.76 | CYP3A4 (0.46) | ALOX5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL18027843 | 0.75 | CYP19A1 (0.43) | ALOX5PSEN1PTGS1PTGS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12156860-B2 | Disorders implicating PUFA oxidation | BIOJIVA LLC (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11166930-B2 | Isotopically modified components and therapeutic uses thereof | RETROTOPE, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| EP-2701698-B1 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE INC (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2012148927-A2 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148930-A2 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148929-A2 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148926-A2 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120088783-A1 | CHROMAN DERIVATIVES | AMPERE LIFE SCIENCES, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8044097-B2 | Chroman derivatives | AMPERE LIFE SCIENCES, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090192179-A1 | CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7514461-B2 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | EDISON PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2005033092-A1 | CHROMAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088783-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | ALOX5 22/4885PSEN1 2723/4885PTGS1 214/4885 |
| US-20090192179-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | ALOX5 22/4885PSEN1 2723/4885PTGS1 214/4885 |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | ALOX5 8/4885PSEN1 7/4885PTGS1 317/4885 |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | CPT1B, PSEN2, NLN | ALOX5 8/4885PSEN1 7/4885PTGS1 317/4885 |
| US-12156860-B2 | Disorders implicating PUFA oxidation | GPX4, CPT1A, FABP1 | ALOX5 7/4885PSEN1 2330/4885PTGS1 224/4885 |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | ALOX5 33/4885PSEN1 1014/4885PTGS1 205/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | ALOX5 7/4885PSEN1 2330/4885PTGS1 224/4885 |
| US-11285125-B2 | Oxidative retinal diseases | ALDH1A2, TXNRD2, STARD3 | ALOX5 33/4885PSEN1 1014/4885PTGS1 205/4885 |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | CPT1B, PSEN2, NLN | ALOX5 8/4885PSEN1 7/4885PTGS1 317/4885 |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | ALOX12, ALOX15, ALOX15B | ALOX5 5/4885PSEN1 1718/4885PTGS1 296/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | ALOX5 20/4885PSEN1 2488/4885PTGS1 938/4885 |
| US-11166930-B2 | Isotopically modified components and therapeutic uses thereof | ACADM, ALDH2, CPT1A | ALOX5 27/4885PSEN1 1986/4885PTGS1 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.